The estimated Net Worth of Todd Robert Nelson is at least $239 mil dollars as of 4 May 2023. Todd Nelson owns over 2,575 units of Telesis Bio Inc stock worth over $231,322 and over the last 2 years Todd sold TBIO stock worth over $7,287.
Todd has made over 1 trades of the Telesis Bio Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Todd sold 2,575 units of TBIO stock worth $7,287 on 4 May 2023.
The largest trade Todd's ever made was selling 2,575 units of Telesis Bio Inc stock on 4 May 2023 worth over $7,287. On average, Todd trades about 644 units every 0 days since 2023. As of 4 May 2023 Todd still owns at least 136,072 units of Telesis Bio Inc stock.
You can see the complete history of Todd Nelson stock trades at the bottom of the page.
Todd's mailing address filed with the SEC is C/O TELESIS BIO INC., 10431 WATERIDGE CIRCLE, SUITE 150, SAN DIEGO, CA, 92121.
Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk, eHuman Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Telesis Bio Inc executives and other stock owners filed with the SEC include: